GlassScriptPhysician profile
Nauveed Iqbal
NPI 1104851492
$2,213.30
in general payments reported to CMS, 2019-2025
30 companies · $54.53 in 2025
The $54.53 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $280 · 2021: $404 · 2022: $292 · 2023: $254 · 2024: $496 · 2025: $54.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $413.49 | 2019-2025 | Wegovy |
| Smith+Nephew, INC. | $368.74 | 2019-2024 | Stravix Mesh, Versajet, Collagenase Santyl |
| Mozarc Medical US LLC | $163.54 | 2024 | Argyle, Palindrome |
| Abbvie INC. | $148.34 | 2020 | |
| Ethicon US, LLC | $110.78 | 2019-2022 | |
| Davol INC. | $105.81 | 2020-2024 | Arista Ah Flexitip |
| Endo Pharmaceuticals INC. | $102.87 | 2019-2023 | Nascobal |
| Baxter Healthcare | $72.91 | 2021-2024 | Renal - Pd, Peri-Strips Dry |
| Integra Lifesciences Corporation | $72.40 | 2023-2024 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Tela Bio, INC. | $57.55 | 2024 | Ovitex 2s |
| Kowa Pharmaceuticals America, INC. | $55.13 | 2022-2023 | Seglentis |
| Medtronic, INC. | $50.36 | 2021-2024 | Progrip |
| Biom'Up France Sas | $45.90 | 2020-2021 | |
| Abbott Laboratories | $44.68 | 2021-2022 | |
| Lemaitre Vascular, INC. | $44.43 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $33.52 | 2019 | |
| Teleflex LLC | $31.71 | 2019-2025 | Solesta |
| Covidien LP | $31.52 | 2019 | |
| Mannkind Corporation | $28.50 | 2019 | |
| Cashflow Solutions, LLC | $27.59 | 2024-2025 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Kerecis Limited | $27.15 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Janssen Pharmaceuticals, INC | $25.26 | 2019 | |
| Bard Peripheral Vascular, INC. | $24.57 | 2023 | |
| Eisai INC. | $24.33 | 2019 | |
| Kci USA, INC. | $23.37 | 2023 | Prevena, V.A.C. Veraflo |
| Cardiovascular Systems INC. | $18.66 | 2021 | |
| Standard Bariatrics, INC. | $17.34 | 2022 | |
| Lilly USA, LLC | $16.77 | 2023 | Zepbound, Jardiance |
| Pacira Pharmaceuticals Incorporated | $13.32 | 2021 | |
| Medtronic Vascular, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nauveed Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.